SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.